drugset / Trial / NCT00190866

Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome

NCT00190866

Phase 3 Completed 210 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy of Duloxetine compared with placebo in the treatment of pain in patients with Fibromyalgia syndrome, with or without major depressive disorder.

Timeline

Start
2005-06
Primary completion
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg
Subject Duloxetine Small molecule 120 mg

Indications